Top Markets
Coin of the day
Delta-Fly Pharma, Inc. Delta-Fly Pharma, Inc.

Delta-Fly Pharma, Inc.

4598
Rank in Stocks #32530
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a... Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.
Share Price
$0.69158324
Market Cap
$9.84M
Change (1 day)
0.00%
Change (1 year)
-84.15%
Country
JP
Trade Delta-Fly Pharma, Inc. (4598)

Category

Earnings for Delta-Fly Pharma, Inc. (4598)
Earnings in 2026 TTM: 0
According to Delta-Fly Pharma, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Delta-Fly Pharma, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE